Pancoast Syndrome

BEDMINSTER, N.J., Jan. 8, 2024 /PRNewswire/ -- Jubilant Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of a first-in-class CoREST (Co-repressor of Repressor Element-1 Silencing Transcription) inhibitor JBI-802 with the dual activity on LSD1 and HDAC6, today announced preliminary safety, pharmacokinetic and initial efficacy results of the Phase I trial in advanced cancer patients. Furthermore, the study results provide a human proof of principle for expanding the development of JBI-802 in Essential Thrombocythemia (ET) and related Myeloproliferative Neoplasms (MPN/MDS) with thrombocytosis. The data from first 11 patients with advanced cancer revealed a dose-proportional increase in exposure across cohorts and a strong correlation between the exposure and the on-target effects of platelet decrease, indicating that pharmacological relevant level of LSD1 inhibition have been achieved. At the same time, platelet decrease is the only adverse event above grade 1 observed in these patients, which differentiates JBI-802 from LSD1-only inhibitors. Specifically, no AEs (Adverse Events) of anemia has been observed, which is potentially due to the positive benefit of inhibition of HDAC6 in erythrocytes. Also, there are no reports of Dysgeusia, an adverse event that has been observed with LSD1-only inhibitors. Among the 11 patients, two were NSCLC (Non-small Cell Lung Cancer) patients, both had progressed on doublet immunotherapy, nivolumab+ipilimumab as first line treatment and both showed anti-tumor activity. Both the patients were treated at lower dose level (10mg) where no relevant decrease of platelets is seen, suggesting that in patients with sensitive tumors this dose can be pharmacologically active with a desirable safety profile. Both NSCLC patients had failed first line treatment with doublet immunotherapy, nivoluman/ipilumab prior to enrolling in the JBI-802 study. The first patient had a STK11 mutation, known to decrease the effectiveness of immunotherapy, present in around 10% of NSCLC patients (higher frequency in lung adenocarcinoma). JBI-802 showed a confirmed partial response in this IO-refractory NSCLC patient with a 39% decrease in the target lung tumor mass. The tumor shrinkage outcome was accompanied by a complete resolution of pancoast syndrome (lung lesion affecting the nerves of brachial plexus). The response appears to be durable after nine cycles and the patient remains on JBI-802 therapy. The second patient had both lung lesion and liver metastasis, which are known to confer resistance to immunotherapy and lead to poor prognosis. Treatment with JBI-802 resulted in over 50% shrinkage of the patient's liver metastasis and a complete resolution of related portal hypertension, edema and improvement of quality of life. Dr. Alexander Starodub, The Christ Hospital - Cincinnati, treating physician for the above patients commented, "The anti-tumor activity seen in these two NSCLC patients is remarkable given the poor prognosis based on their genetic and metastatic pattern. The 10 mg dose of JBI-802 was well-tolerated without any clinically significant adverse effects and the initial clinical data suggest a good therapeutic index for JBI-802." Preclinical studies showed a synergistic anti-tumor effect by combining immunotherapy and JBI-802 in xenograft models. In addition, the CoREST inhibition was reported to sensitize immunotherapy resistant tumors, especially those with STK11 mutations. Taken together, the preliminary efficacy data from the JBI-802 Phase I study suggest the opportunity that a combination between immunotherapy and JBI-802 could bring a new therapy option to such patient populations with limited treatment options. In addition, the on-target dose/exposure-proportional decrease in platelet constitute a proof-of-principle that JBI-802 can be an active compound in hematological malignancies like Essential Thrombocythemia (ET) and other MPN/ MDS characterized by thrombocytosis. A follow up Phase I/II study in MPN/ET and MPN/MDS with thrombocytosis is being planned for early next year to investigate JBI-802 as potential novel treatment option. About Jubilant Therapeutics Inc. Jubilant Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients. Its advanced structure-based discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships including with Blueprint Medicines for a brain penetrant EGFR Exon-20 program. The Company's pipeline consists of a first in class dual coREST modifier, JBI-802, currently in a Phase I/II clinical trial in multiple tumors, a novel brain-penetrant modulator of PRMT5 for which an IND has been accepted, brain penetrant and gut restrictive PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications. The Company is headquartered in Bedminster, New Jersey and guided by globally renowned scientific advisors. For more please visit: Twitter @JubilantTx, LinkedIn Photo: Logo:

The researchers from Chiropractic Doctors Association of Hong Kong (CDAHK) released their case studies on chronic headaches and neck pain.NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Chiropractors may reduce the number of monthly neck pain and headaches for people who have chronic and complicated type of history, four case studies (1-4) published in 2022 American Journal of Case Reports, found.Chronic headaches involve a painful sensation in any part of the head, ranging from sharp to dull, that may occur with other symptoms at least 15 days per month. Continue Reading Committees of Chiropractic Doctors Association of Hong Kong Chiropractors provide long-term relief from chronic headaches, said Eric Chu, principal investigator of the studies and Chairman of Chiropractic Doctors Association of Hong Kong. "Our recent studies(4-12) have also found that chiropractic may be effective for episodic neck pain and chronic headaches. These studies are successful cases showing that chiropractic is effective specifically for patients who failed with traditional therapy," Chu added."Since chronic headaches with complicated medical history are often more difficult to treat, and the pain medicines used have multiple potential side effects, the results are promising," said Dr. Kingsley Leung, Executive Committee of CDAHK.Multi-model chiropractic therapies involve achieving proper alignment of the spine, which consisted of spinal manipulation, micro-vibration and microcurrent technology to flush out lactic acid and untie deep knots, and robotic spinal decompression for non-surgical intervertebral relief. Non-invasive treatments can plan access to the spine through using a computer-guided robot and traction therapy to safely and effectively elongate and stretch the spine."To achieve a optimal treatment effect of chiropractic therapy, technology is important," Chu said. "The care providers should try their best to use the current technology at each spinal problem.""For patients who do not want to use prescription pain medication, chiropractor offers a hopeful alternative. Treating chronic pain is a multidisciplinary approach, and chiropractic is one of best treatment options that should be considered," Chu said.References 1. Chu EC, Trager RJ, Ng GSN, Shum JSF. Neck pain and Headache Complicated by Persistent Syringomyelia After Foramen Magnum Decompression for Chiari I Malformation: Improvement with Multimodal Chiropractic Therapies. Am J Case Rep. 2022 Oct 31;23:e937826. 2. Chu EC, Trager RJ, Ng GSN, Shum JSF. Neck pain and Headache Complicated by Persistent Syringomyelia After Foramen Magnum Decompression for Chiari I Malformation: Improvement with Multimodal Chiropractic Therapies. Am J Case Rep. 2022 Oct 31;23:e937826. 3. Chu EC, Trager RJ, Tao C, Lee LY. Chiropractic Management of Neck Pain Complicated by Symptomatic Vertebral Artery Stenosis and Dizziness. Am J Case Rep. 2022 Oct 19;23:e937991. 4. Chu EC, Trager RJ, Chen AT. Concurrent Bell's Palsy and Facial Pain Improving with Multimodal Chiropractic Therapy: A Case Report and Literature Review. Am J Case Rep. 2022 Sep 19;23:e937511. 5. Chu EC, Lin AFC (2022) Relief of postural orthostatic tachycardia syndrome with chiropractic rehabilitation Journal of Family Medicine and Primary Care 11: 7. 4006-4009 July. 6. Chu EC. Reducing Cervical Retrolisthesis With Long-Term Monthly Chiropractic Maintenance Care: A Case Report. J Med Cases. 2022 Jul;13(7):359-364. 7. Chu EC, Trager RJ, Shum JSF, Lai CR. Pancoast Tumor Presenting as Neck Pain in the Chiropractic Office: A Case Report and Literature Review. Am J Case Rep. 2022 Jul 7;23:e937052. 8. Chu ECP, Lee LYK. Adjacent segment pathology of the cervical spine: A case report. J Family Med Prim Care. 2022 Feb;11(2):787-789. 9. Eric Chun-Pu Chu (2022) Remission of Headache and Neck Pain Following Chiropractic Manipulative Treatment in a Patient with Neurofibromatosis Chiropractic Journal of Australia 49: 1. 8-18 Feb 10. Chu EC. Preventing the progression of text neck in a young man: A case report. Radiol Case Rep. 2022 Jan 18;17(3):978-982. 11. Chu ECP. Alleviating cervical radiculopathy by manipulative correction of reversed cervical lordosis: 4 years follow-up. J Family Med Prim Care. 2021 Nov;10(11):4303-4306. 12. Chu ECP, Spaska A, Monov D, Kasatkin M, Stroiteleva N. Examining the correlation between salivary cytokine concentrations and CRP in people experiencing social-cognitive stress. Neurol Res. 2022 Oct 5:1-6. 13. Chu ECP. Alleviating cervical radiculopathy by manipulative correction of reversed cervical lordosis: 4 years follow-up. J Family Med Prim Care. 2021 Nov;10(11):4303-4306. This press release was issued through 24-7PressRelease.com. For further information, visit . SOURCE Chiropractic Doctors Association of Hong Kong (CDAHK)

According to Dr Eric Chun-Pu Chu, DC PhD, of Chiropractic Doctors Association of Hong Kong (CDAHK), people spend about 6 hours a day gazing at their mobile phones, which can cause major text-neck aches and numbness. LOS ANGELES, Sept. 5, 2022 /PRNewswire/ -- According to the research study at Journal of Medical Cases, spinal manipulative therapy is effective in correcting out of alignment in the neck (1). What text neck does to your body is as follows: It put the neck in the wrong position: lengthens the tendons, and ligaments behind the neck while misaligning and tightening the neck. "Our heads weigh ten pounds. The weight your neck must support doubles for every inch your head is inclined forward. That additional tension builds up over time," according to CDAHK. Continue Reading Text Neck with chiropractic maintenance care It usually starts with pain in the neck, shoulders, or back. It could also give you a sharp pain, a headache, stiffness in your neck or jaw, or numbness in your arms and hands. The condition happens when the neck is in an odd position, which puts stress on the cervical spine and the muscles that support it. This is what happens when you bend your neck forward for a long time to look at your screen or phone. However, giving up our gadgets isn't really an option. Instead, we may ensure that we attend maintenance care and adopt healthy routines to avoid the aches and pains related to text neck. Chiropractors recommend for getting adjusted if you feel persistent pain. The monthly care helps ease pain and repair the structural problems that text neck over time generates. Chiropractic care was named as one of the main non-pharmacological treatments for acute and chronic neck (1-4), shoulder (5), and back pain (6-9). Therefore, keep in mind that no one tool is certain to relieve your tech-related symptoms. But in the end, remaining good habits and exercising don't hurt to maintain your muscles supple and active. Reference Chu EC. Reducing Cervical Retrolisthesis With Long-Term Monthly Chiropractic Maintenance Care: A Case Report. J Med Cases. 2022 Jul;13(7):359-364. Chu EC. Preventing the progression of text neck in a young man: A case report. Radiol Case Rep. 2022 Mar;17(3):978-982. Chu ECP, Lee LYK. Adjacent segment pathology of the cervical spine: A case report. J Family Med Prim Care. 2022 Feb;11(2):787-789. Chu EC, Trager RJ, Shum JSF, Lai CR. Pancoast Tumor Presenting as Neck Pain in the Chiropractic Office: A Case Report and Literature Review. Am J Case Rep. 2022 Jul 7;23:e937052. Chu EC. Shoulder Injury Related to Vaccine Administration (SIRVA) in 16 Patients Following COVID-19 Vaccination Who Presented to Chiropractic, Orthopedic, and Physiotherapy Clinics in Hong Kong During 2021. Med Sci Monit. 2022 Jul 11;28:e937430 Chu EC, Trager RJ. Effectiveness of Multimodal Chiropractic Care Featuring Spinal Manipulation for Persistent Spinal Pain Syndrome Following Lumbar Spine Surgery: Retrospective Chart Review of 31 Adults in Hong Kong. Med Sci Monit. 2022 Aug 2;28:e937640. Chu EC, Trager RJ, Chen ATC. Conservative Management of Low Back Pain Related to an Unresectable Aggressive Sacral Hemangioma: A Case Report. Am J Case Rep. 2022 Jun 23;23:e936984. Chu EC. Large abdominal aortic aneurysm presented with concomitant acute lumbar disc herniation - a case report. J Med Life. 2022 Jun;15(6):871-875. Chu EC, Leung KKY. Chiropractic Management of Symptomatic Pedicle Hemangioma: a Case Report. Maedica (Bucur). 2022 Jun;17(2):528-531. This press release was issued through 24-7PressRelease.com. For further information, visit . SOURCE Chiropractic Doctors Association of Hong Kong (CDAHK)